Patent · US Active

Compounds which selectively modulate the CB2 receptor

US8735430B2 · kind B2 · utility

6Cited by

42References

13Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Alessandra Bartolozzi · Norwalk, US
Eugene Richard Hickey · Danbury, US
Doris Riether · Biberach an der Riß, DE
Lifen Wu · New Milford, US
Renee M. Zindell · New Milford, US
Nigel James Blumire · Biggenden, AU
Monika Ermann · Wantage, GB
Edward Glenn · Abingdon, GB
Someina Khor · Abingdon, GB
Przemyslaw Zawadzki · Skawina, PL

Key dates

Filing date	Sep 26, 2012
Grant date	May 27, 2014
Priority date	—
Expiry date	Sep 26, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds of formula (I)are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.